Einloggen
Einloggen
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrieren
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Startseite
  2. Aktien
  3. Australien
  4. Australian Stock Exchange
  5. Bionomics Limited
  6. News
  7. Andere Sprachen
    BNO   AU000000BNO5

BIONOMICS LIMITED

(BNO)
  Bericht
Verzögert Australian Stock Exchange  -  05:22 30.09.2022
0.0520 AUD   -3.70%
25.08.Bionomics Limited meldet Ergebnis für das Geschäftsjahr zum 30. Juni 2022
CI
08.08.Bionomics sichert sich $1 Million F&E-Steuernachlass
MT
14.03.Bionomics erhält $190.000 an Lizenzeinnahmen; Aktien rutschen um 3% ab
MT
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivateFonds 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über BIONOMICS LIMITED
21.09.Bionomics to Host KOL Webinar on BNC210 and Social Anxiety Disorder
19.09.Bionomics Limited(ASX:BNO) dropped from S&P/ASX Emerging Companies..
31.08.Bionomics to Participate in Upcoming September Investor Conferences
25.08.Bionomics reports Full Year Financial Results
25.08.Bionomics Limited Reports Earnings Results for the Full Year Ended June 30, 2022
08.08.Bionomics Receives R&D Tax Incentive Refund for FY2021 of A$2.1M
08.08.Bionomics Secures $1 Million R&D Tax Rebate
08.07.Bionomics to Participate in William Blair's Biotech Focus Conference 2022
27.06.Bionomics Limited to Participate in the H.C. Wainwright Mental Health Conference
14.06.Certain Warrants of Bionomics Limited are subject to a Lock-Up Agreement Ending on 14-J..
14.06.Certain Options of Bionomics Limited are subject to a Lock-Up Agreement Ending on 14-JU..
14.06.Certain Common Stock of Bionomics Limited are subject to a Lock-Up Agreement Ending on ..
13.06.Bionomics Investor Webinar
16.05.Bionomics Limited to Participate in Upcoming Investor Conferences
14.03.Bionomics Receives $190,000 in Licensing Revenue; Shares Slip 3%
13.03.Bionomics Limited Receives $ AUD 263,634 Licensing Revenue from Cancer Therapeutics CRC
24.02.Bionomics' Half-Year Report
23.02.Bionomics Limited Reports Earnings Results for the Half Year Ended December 31, 2021
15.02.Actinogen Medical Names New Chief Medical Officer; Shares Rise 4%
28.01.Bionomics : Quarterly Activities/Appendix 4C Cash Flow Report Dec 2021
19.01.Bionomics : Becoming a substantial holder
14.01.Bionomics : Becoming a substantial holder
09.01.Bionomics : Presentation for H.C. Wainwright BioConnect 2022
06.01.Bionomics Increases ADS Public Offering Proceeds to $23 Million
05.01.Bionomics : Application for quotation of securities - BNO
05.01.Bionomics : Proposed issue of securities - BNO
05.01.Bionomics Limited announced that it has received $2.794495 million in funding
04.01.Bionomics Starts Phase 2 Clinical Trial of Social Anxiety Disorder Drug; Shares Decline..
03.01.Bionomics Begins Mid-Stage Trial of BNC210 in Social Anxiety Disorder
03.01.Bionomics Initiates Phase 2 Prevail Study of Bnc210 for the Acute Treatment of Social A..
2021Bionomics Limited Announces Resignation of Mitchell Kaye as Non-Executive Director, Eff..
2021Bionomics : Becoming a substantial holder
2021Bionomics : Notification regarding unquoted securities - BNO
2021Bionomics Limited(NasdaqGM:BNOX) added to NASDAQ Composite In..
2021Bionomics Shares Surge After US Initial Public Offering by Developer of Treatments for ..
2021Bionomics Limited Prices US IPO at $12.35/ADS
2021Bionomics : Proposed issue of securities - BNO
2021Bionomics Launches $25 Million IPO in US
2021Bionomics : 2021 New Constitution
2021Bionomics : 2021 AGM Executive Chairman's Presentation
2021Bionomics Secures US FDA Fast Track Designation for Social Anxiety Disorder Drug
2021U.S. Food and Drug Administration Grants Bionomics Fast Track Designation to Bnc210 for..
2021Bionomics Files for US IPO
2021Bionomics : BNO Quarterly Activities Report
2021Australia's Bionomics Ltd. Files for IPO With U.S. SEC
2021Application for quotation of securities - BNO
2021Bionomics Secures US FDA Clearance for Phase 2 Social Anxiety Disorder Trial
2021FDA Clears Bionomics Limited's BNC210 Ph2 Social Anxiety Disorder IND
2021Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disord..
2021Bionomics Limited(ASX:BNO) added to S&P/ASX Emerging Companies Ind..
2021Bionomics : to Commence Clinical Trial of Anxiety Disorder Drug by 2021-end
2021Bionomics Limited Reports Earnings Results for the Full Year Ended June 30, 2021
2021Bionomics : to Go Public in the US; Shares Jump 10%
2021Bionomics plans to Conduct A Registered IPO of ADSs in the Us and Concurrent Listing of..
2021Bionomics Initiates Phase 2B ATTUNE Study of BNC210 in PTSD
2021Bionomics Limited Announces Executive Changes
2021Bionomics Limited Announces Change of Registered Office Address, Effective 21 June 2021
2021Bionomics BNC210 Expansion into Social Anxiety Disorder
2021Bionomics : Expands Use of Therapy Compound to Social Anxiety Disorder
2021Bionomics : Pays Outstanding Debts
2021Bionomics Limited Announces Early Repayment of Debt
2021Bionomics : Agilex Biolabs Congratulates Bionomics Limited on BNC210 PK Results
2021Bionomics Limited Announces Executive Changes
2021Bionomics Limited Announces Change of Company Secretary
2021Bionomics : Launching $15 Million Entitlement Offer; Shares Rise 5%
2021Bionomics : Narrows Fiscal First Half Loss as Company Records Other Gains
2021Bionomics Limited Announces Positive BNC210 PK Results for Solid Dose Formulation
2021Bionomics Limited and EmpathBio Inc Joint Feasibility Assessment
2021Bionomics : Raises Over $12 Million in Placement to Progress Clinical Trial; S..
2021Bionomics Limited Completes Treatment Phase in the MODULATE Clinical Trial
2021Bionomics Limited Announces Publication of Positive BNC210 Phase 2a Data in Gad Patient..
2021Bionomics : to Begin Pharmacokinetic Study of PTSD Treatment Drug in Tablet Fo..
2021Bionomics Limited Initiates 7-Day Dosing Pharmacokinetic Study of BNC210
2020Bionomics : Jumps 8% After Licensing Anticancer Drug Candidate
2020Bionomics Limited Licenses Drug Candidate BNC101 to Carina Biotech
2020Bionomics Limited Announces Director Changes
2020Bionomics Limited announced that it has received AUD 5.43332 million in funding from Ap..
2020Bionomics Limited Provides Update on the Development of BNC210
2020Bionomics Limited Reports Earnings Results for the Full Year Ended June 30, 2020
2020Bionomics Limited Announces Amendment to the US Bank Loan Facility
2020Bionomics Limited Appoints Aaron Weaver as Non-Executive Director to the Board of Biono..
2020Bionomics : Recapitalisation Led by Sophisticated Life Sciences Investor - Apeiron Investm..
2020Bionomics Limited announced that it expects to receive AUD 5.43332 million in funding f..
2020Bionomics Limited Extends Cash Runway Through Deferral of Loan Repayments
2020Bionomics Limited Announces Recruitment Completed in the Phase 2 BNC105 / Nivolumab Com..
2020Bionomics Limited Announces Publication of Positive Phase 2a Data for BNC210 in General..
2020Bionomics Limited Announces Publication of Positive Phase 2a Data or BNC210 in Generali..
2020Bionomics Limited and MSD Scientists Publish Preclinical Findings for BNC375 in Peer-Re..
2020Bionomics : and MSD Scientists Publish Preclinical Findings for BNC375 in Peer-Reviewed Jo..
2020Domain Therapeutics SA completed the acquisition of NEUROFIT SAS and Prestwick Chemical..
2020Bionomics Limited Reports Earnings Results for the Half Year Ended December 31, 2019
2019Bionomics : Sale of Bionomics' French Subsidiaries to Domain Therapeutics
2019Domain Therapeutics SA made an offer to acquire NEUROFIT SAS and Prestwick Chemical, In..
2019Bionomics : Announces Fast Track Designation Granted by U.S. FDA to BNC210 Development Pro..
2019Bionomics Announces Fast Track Designation Granted by U.S. FDA to BNC210 Development Pr..
2019Bionomics Limited Announces Positive Results from A Pharmacokinetic Study in Healthy Vo..
2019Bionomics Limited(ASX:BNO) dropped from S&P/ASX Emerging Companies..
2019Bionomics Limited Announces Positive Feedback from the FDA At the Recent Type C Meeting..
2019Bionomics Limited Reports Earnings Results for the Full Year Ended June 30, 2019
2019Bionomics Limited Announces Top Line Results of the Exploratory Trial of BNC210 for the..
Anstehende Termine für BIONOMICS LIMITED